ClinicalTrials.gg

Program

etavopivat

Also written as “Etavopivat”, “Etavopivat Tablets Low dose” and “Etavopivat Tablets High dose”.

Its studies are mostly in Anemia, Sickle Cell · Thalassemia · Anemia · Liver Diseases, led by Novo Nordisk.

Furthest: phase 3, since Nov 5, 202012 company-led studies, 4 open or runningNext primary completion: Aug 20, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novo Nordisk124 open or runningphase 3since Nov 5, 2020Nov 5, 2020Aug 20, 2027phase 2 · NCT05953584
  • Named in Novo Nordisk’s own pipeline as Etavopivat, phase 3, as of Nov 5, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 5, 2020First study: phase 3 study in Anemia, Sickle CellFirst studyNCT04624659 · 450 enrolled · United States, Canada, Egypt and more
  2. Jul 22, 2021Phase 2 study in Anemia, Sickle CellNCT04987489 · 53 enrolled · United States, Canada, Egypt and more
  3. Sep 15, 2022Phase 2 study in AnemiaNCT05568225 · 17 enrolled · United States, Canada, France and more
  4. Jan 23, 2023Phase 2 study in Anemia, Sickle CellNCT05725902 · 12 enrolled · United States
  5. Jul 11, 2023Phase 2 study in Anemia, Sickle CellNCT05953584 · 27 planned · India, Nigeria, Oman
  6. Dec 27, 2023Phase 2 study in Anemia, Sickle CellNCT06198712 · 95 planned · Canada, France, Kenya and more
  7. Mar 22, 2024Phase 1 study in Liver DiseasesNCT06336018 · 48 enrolled · United States
  8. May 22, 2024Phase 1 study in ThalassemiaNCT06433661 · 16 enrolled · United States
  9. Aug 30, 2024Phase 1 study in Anemia, Sickle CellNCT06581627 · 24 enrolled · China
  10. Sep 23, 2024Phase 3 study in Anemia, Sickle CellNCT06612268 · 510 planned · United States, Australia, Belgium and more
  11. Feb 3, 2025Phase 1 study in ThalassemiaNCT06813924 · 37 enrolled · United States
  12. Jun 8, 2025Phase 1 study in Anemia, Sickle CellNCT07023029 · 33 enrolled · United States

Ahead

  1. Aug 20, 2027Primary completion: phase 2 study in Anemia, Sickle CellNCT05953584
  2. Aug 27, 2027Primary completion: phase 3 study in Anemia, Sickle CellNCT06612268
  3. Feb 23, 2028Primary completion: phase 2 study in Anemia, Sickle CellNCT06198712

TargetBeta

“An orally available, small-molecule allosteric activator of the selective red blood cell (RBC) isoform of pyruvate kinase (PK-R), with potential to improve symptoms in sickly cell disease (SCD) patients. Upon oral administration, etavopivat allosterically binds to and activates PK-R, thereby enha…”NCIt, read by Claude
“Pyruvate kinase isozymes R/L activator”ChEMBL 37, by rule

Other programs on PKLR

ProgramCompanyFurthest phaseStudies
mitapivatruleAgios Pharmaceuticalsphase 424

Studies

All 12 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07023029Anemia, Sickle Cell · United States1CompletedSep 12, 202533
NCT06813924Thalassemia · United States1CompletedMay 27, 202537
NCT06612268Anemia, Sickle Cell · United States, Australia, Belgium and more3RecruitingAug 27, 2027510
NCT06581627Anemia, Sickle Cell · China1CompletedOct 31, 202424
NCT06433661Thalassemia · United States1CompletedJul 6, 202416
NCT06336018Liver Diseases · United States1CompletedAug 1, 202548
NCT06198712Anemia, Sickle Cell · Canada, France, Kenya and more2RecruitingFeb 23, 202895
NCT05953584Anemia, Sickle Cell · India, Nigeria, Oman2RecruitingAug 20, 202727
NCT05725902Anemia, Sickle Cell · United States2CompletedMar 9, 202612
NCT05568225Anemia · United States, Canada, France and more2TerminatedJul 15, 202417
NCT04987489Anemia, Sickle Cell · United States, Canada, Egypt and more2CompletedSep 3, 202553
NCT04624659Anemia, Sickle Cell · United States, Canada, Egypt and more3Active, not recruitingFeb 6, 2026450

How it is read

Names in the registry

  • “Etavopivat”, 10 entries
  • “Etavopivat Tablets Low dose”, 1 entry
  • “Etavopivat Tablets High dose”, 1 entry
  • “Etavopivat Tablets”, 1 entry
  • “Etavopivat tablets”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.